Dec. 17, 2007 |
Caliper Life Sciences has launched a new screening service to help researchers determine the efficacy of combination drug therapies and identify potentially harmful combinations before therapies enter clinical trials through their Caliper Discovery Alliances & Services (CDAS). Cellular assays are used to screen for synergistic compound combinations and flag potentially harmful toxicity levels. Assays include Caliper's anti-cancer cell proliferation panel, cellular cytokine/chemokine release assays, or using in vivo efficacy models.
Product: Drug Combination Services through Caliper Discovery Alliances and Services
Company: Caliper Life Sciences
For More Information: www.caliperls.com